Avian Flu Drug Zanamivir Clears SFDA For Clinical Trials
This article was originally published in PharmAsia News
A bird flu drug developed by Shanghai Institute of Materia Medica, Nanjing Xian Sheng Dong Yuan Pharmaceutical and Nanjing Yifang Center for Pharmaceutical R&D have passed preclinical appraisal of China's State FDA Center for Drug Evaluation. The zanamivir capsule and its raw material drug received SFDA's approval Nov. 7 to enter clinical trials. Zanamivir, a neuraminidase inhibitor for the treatment of influenza caused by type A virus, is the second most effective avian flu drug after oseltamivir. (Click here for more - Chinese Language)
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.